STOK - Stoke Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Stoke Therapeutics, Inc.

45 Wiggins Avenue
Bedford, MA 01730
United States

Full Time Employees32

Key Executives

NameTitlePayExercisedYear Born
Dr. Edward M. KayeCEO & Director648.9kN/A1949
Dr. Adrian R. KrainerCo-Founder & Director100kN/A1959
Dr. Huw M. Nash Ph.D.COO, Chief Bus. Officer & Sec.429.67kN/A1967
Dr. Barry S. TichoChief Medical Officer501.15kN/A1960
Ms. Isabel AznarezCo-Founder, VP & Head of BiologyN/AN/A1972
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Corporate Governance

Stoke Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.